Company intelligence / Profile preview

neuMirRx

Ownership: Private
Development stage: Other

Overview

NeuMiRx is a preclinical-stage biotechnology company focused on developing novel microRNA-based therapeutics for the treatment of neurodegenerative and neurological disorders. The company leverages a proprietary platform to identify and modulate specific microRNA signatures associated with disease progression in conditions such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease. By targeting these small non-coding RNA molecules, NeuMiRx aims to restore healthy gene expression patterns and provide neuroprotective benefits. Their approach represents a precision medicine strategy within the central nervous system (CNS) space, addressing significant unmet medical needs in brain health.

Therapeutic areas: Neurology
Modalities: RNA therapymicroRNA-based therapySmall molecule
Industry: Biotech

Beyond the preview

Go deeper on neuMirRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on neuMirRx.

Explore the full profile